Balchem Corporation

Equities

BCPC

US0576652004

Specialty Chemicals

Market Closed - Nasdaq 04:00:00 2024-04-15 pm EDT 5-day change 1st Jan Change
146.8 USD -0.77% Intraday chart for Balchem Corporation -3.95% -1.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Balchem Corporation Announces Management Changes CI
Balchem Insider Sold Shares Worth $840,985, According to a Recent SEC Filing MT
Balchem Insider Sold Shares Worth $1,700,613, According to a Recent SEC Filing MT
Tranche Update on Balchem Corporation's Equity Buyback Plan announced on August 6, 1999. CI
Balchem Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Balchem Corporation, Q4 2023 Earnings Call, Feb 16, 2024
Balchem's Q4 Adjusted Earnings Rise, Net Sales Fall MT
Earnings Flash (BCPC) BALCHEM CORPORATION Posts Q4 Revenue $228.7M MT
Earnings Flash (BCPC) BALCHEM CORPORATION Reports Q4 EPS $0.95 MT
Balchem Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : S&P 500 Seen Grinding to New High; PPI Data in Focus DJ
Global stocks at two-year highs, Nikkei skirts record RE
Balchem Lifts Dividend to $0.79, Payable Jan. 19 to Holders of Record Dec. 27 MT
Balchem Corporation Announces Dividend, Payable on January 19, 2024 CI
HC Wainwright Cuts Price Target on Balchem to $135 From $165, Maintains Buy Rating MT
Tranche Update on Balchem Corporation's Equity Buyback Plan announced on August 6, 1999. CI
Transcript : Balchem Corporation, Q3 2023 Earnings Call, Oct 27, 2023
Balchem Q3 Adjusted Earnings Rise, Net Sales Fall MT
Earnings Flash (BCPC) BALCHEM CORPORATION Posts Q3 Revenue $229.9M MT
Earnings Flash (BCPC) BALCHEM CORPORATION Posts Q3 EPS $1.04 MT
Balchem Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
According to a Recent SEC Filing, Balchem Insider Sold Shares Worth $499,979 MT
Balchem Corporation Announces Board Appointments, Effective as of September 6, 2023 CI
HC Wainwright Adjusts Price Target on Balchem to $165 From $150, Maintains Buy Rating MT
Tranche Update on Balchem Corporation's Equity Buyback Plan announced on August 6, 1999. CI
Chart Balchem Corporation
More charts
Balchem Corporation develops, manufactures, distributes and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition and industrial markets. The Company's segments include Human Nutrition and Health (HNH), Animal Nutrition and Health (ANH), and Specialty Products. The HNH segment provides human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. This segment also manufactures specialty vitamin K2, which plays a role in the human body for bone health, heart health and immunity, and methylsulfonylmethane (MSM). ANH segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to the nutrient choline chloride. Through Specialty Products, it re-packages and distributes a number of gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
146.8 USD
Average target price
154.3 USD
Spread / Average Target
+5.16%
Consensus
  1. Stock Market
  2. Equities
  3. BCPC Stock
  4. News Balchem Corporation
  5. HC Wainwright Adjusts Balchem's Price Target to $170 from $160, Keeps Buy Rating